Compare Novo Nordisk A/S (NVO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Realty Income Corp — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while Realty Income Corp trades at $62.58 (market cap $58.56B). The key difference: Novo Nordisk A/S is far larger — about 3.5× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.25%). Which is the better fit depends on your goals.
| NVO | O | |
|---|---|---|
Market Cap | $207.85B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $63.98 | $67.56 |
52-Week Low | $35.29 | $55.93 |
Enterprise Value | $222.55B | $89.19B |
Dividend Yield | 3.81% | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Realty Income (O) trades at $62.36, up 0.76% with bearish technical signals despite recent earnings misses. The REIT maintains strong fundamentals with $5.75B revenue, 21.23% net margins, and consistent dividend payments. Recent $875M convertible notes offering signals growth ambitions while technical indicators show oversold conditions with RSI at 23.55.
Outlook remains balanced with analyst consensus at $67.29 target (8% upside) despite recent earnings disappointments. Key opportunities include dividend reliability (673 consecutive payments) and data center expansion, while risks involve rising debt levels (39.93% debt-to-asset) and interest rate sensitivity. The stock offers income stability with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
